About Our Plasma Trials

Outpatient COVID-19 Plasma Research Study for Prevention (CSSC-001)

Convalescent Plasma to Stem Coronavirus: A Randomized Controlled Double-Blinded Phase 2 Study Comparing the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 non-immune plasma) Among Adults Exposed to COVID-19

This randomized, controlled, double-blinded phase 2 trial will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma as prophylaxis following exposure to COVID-19. Adults 18 years of age and older with high-risk exposure as defined by the CDC may participate. We will randomize 500 eligible subjects in a 1:1 ratio to receive either high-titer anti-SARS-CoV-2 plasma or control (SARS-CoV-2 non-immune plasma).

ClinicalTrials.gov Identifier: NCT04323800

---

Early Outpatient COVID-19 Plasma Treatment Research Study (CSSC-004)

Convalescent Plasma to Limit Coronavirus-Associated Complications: A Randomized, Double-Blind, Controlled, Phase 2 Study Comparing the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 non-immune) Plasma Among Outpatients with Symptomatic COVID-19 

This randomized, double-blind, controlled, phase 2 trial will assess the efficacy and safety of Human Coronavirus Immune Plasma (HCIP) to reduce the risk of hospitalization or death, the duration of symptoms, and duration of nasopharyngeal or oropharyngeal viral shedding. Adults 18 years of age or older, regardless of risk factors for severe illness, may participate. Approximately 600 eligible subjects stratified 50:50 in the <65 vs. ≥65 age range will be randomized in a 1:1 ratio to receive either HCIP or control plasma.

ClinicalTrials.gov Identifier: NCT04373460